Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Chokri Ben Lamine: Clinical Insights into Glanzmann Thrombasthenia and Heavy Menstrual Bleeding
Chokri Ben Lamine/X
Apr 21, 2026, 12:50

Chokri Ben Lamine: Clinical Insights into Glanzmann Thrombasthenia and Heavy Menstrual Bleeding

Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:

”Glanzmann Thrombasthenia and Severe Menorrhagia – High-Yield Pearls

Glanzmann thrombasthenia (GT) is caused by defect in GPIIb/IIIa (αIIbβ3)

Platelet count normal but aggregation absent resulting in severe mucosal bleeding

Menorrhagia is a major morbidity driver in GT

It leads to recurrent transfusion requirements iron deficiency anemia

Key principle:

  • Bleeding is a platelet function problem and give functional platelets
  • Platlet transfusion is the cornerstone of therapy in severe bleeding

Rationale:

  • GT platelets lack GPIIb/IIIa
  • Transfused normal donor platelets restore aggregation
  • Provide functional fibrinogen bridging, resulting in a stable clot

This is pathophysiologically targeted therapy

Indication for platelets:

  • Severe menorrhagia (Hb drop / hemodynamic impact)
  • Active uncontrolled bleeding
  • Pre-procedure

Preferred product:

  • Single-donor apheresis platelets
  • Reduce alloimmunization risk

Major limitation:

Alloimmunization to:

  • HLA antigens
  • GPIIb/IIIa

Consequence:

  • Platelet refractoriness leads to reduced efficacy

Therefore:

  • Use platelets judiciously but early when indicated

Adjunct therapy (always combine):

Tranexamic acid (TXA)

  • Stabilizes clot
  • Dose: 1–1.5 g PO/IV q8h

Hormonal therapy

  • Combined OCPs or progesterone
  • Decreased endometrial shedding

Iron replacement

  • Oral or IV

If platelet refractoriness OR antibodies present:

  • rFVIIa (NovoSeven® – eptacog alfa)

Dose:

  • 90 µg/kg IV q2–3h

Mechanism:

  • Generates thrombin independent of platelet aggregation

rFVIIa is second-line therapy, not first-line.

Avoid overusing rFVIIa early if platelets still effective

Acute severe menorrhagia algorithm:

  • Stabilize patient with IV fluids, with or without RBC transfusion.
  • Start TXA immediately
  • Give platelet transfusion early
  • Add hormonal therapy
  • If refractory, give rFVIIa.

Transfusion thresholds:

  • Hemoglobin less than 7–8 or symptomatic leads to RBC transfusion

Avoid:

  • NSAIDs
  • Antiplatelets
  • IM injections

Long-term prevention:

  • Continuous OCPs
  • LNG-IUS (Mirena® – levonorgestrel IUD)
  • Cyclic TXA during menses

Goal:

  • Minimize need for platelet transfusions

Special situations:

  • Adolescents require early hormonal control
    Pregnancy requires MDT (hematology plus OB)

Pre-procedure:

  • Platelets with or without TXA with or without rFVIIa depending on severity

Key clinical insight:

  • Platelets treat the defect, whereas rFVIIa bypasses it

Always prioritize platelet transfusion FIRST in severe bleeding

Preserve platelet efficacy by avoiding unnecessary exposure.

Use combined mechanistic and supportive therapy.

OSCE Scenario:

  • 20F GT, Hb 6.8, ongoing heavy bleeding
  • TXA plus RBC transfusion and apheresis platelets FIRST
  • If poor response, rFVIIa

MCQ:

First-line therapy in severe GT menorrhagia (no antibodies)?
A) rFVIIa
B) TXA alone
C) Platelet transfusion
D) Warfarin

Answer: C – replaces defective platelet function.”

More posts featuring Chokri Ben Lamine on Hemostasis Today.

Chokri Ben Lamine Health Hematology Hemophilia Hemostasis News Hemostasis Today Medicine thrombosis
NewsFeed